Publication | Closed Access

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Open-label TrialCell TherapyTransplantationMarrow TransplantationStem Cell TransplantationImmunologyHematologyTransplantation MedicineAllogeneic Haematopoietic Stem-cellBlood TransplantationImmunotherapyMedicineCell TransplantationGraft RejectionPhase 3